Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A pediatric-inspired chemo regimen for acute lymphoblastic leukemia (ALL) shows lasting results in adolescents and young adults, with a 10-year overall survival rate of 56%, per the long-term CALGB 10403 follow-up. Late relapses were rare but mostly seen in B-cell ALL patients. Notably, less than 40% of patients finished the full treatment plan due to toxicity or nonadherence.
A decade of follow-up data from the CALGB 10403 trial confirms that pediatric-inspired chemotherapy can deliver durable survival benefits for adolescents and young adults (AYAs) with Philadelphia chromosome-negative (Ph-negative) acute lymphoblastic leukemia (ALL). The prospective phase 2 study enrolled 295 patients aged 16–39 and tracked outcomes over a median of 120 months — offering some of the most comprehensive long-term data available for this population.
The results are encouraging but come with caveats. While survival rates held up over time, late relapses — though uncommon — occurred almost exclusively in B-cell ALL patients. A major real-world hurdle also emerged: only 39% of patients completed the planned therapy, with toxicity and nonadherence being the primary culprits.
By the Numbers:
Why it matters: These findings reinforce pediatric-inspired regimens as a viable long-term strategy for AYA ALL patients, while highlighting obesity and high CRLF2 expression as key risk factors. The low therapy completion rate signals an urgent need for better toxicity management and adherence support in future trial designs.
